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Background
Among the currently available prognostic models for diffuse large B-cell lymphoma 
(DLBCL), we investigated to determine which is most adoptable for DLBCL patients treat-
ed with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone 
(R-CHOP) followed by upfront autologous stem cell transplantation (auto-SCT).
Methods
We retrospectively evaluated survival differences among risk groups based on the 
International Prognostic Index (IPI), the age-adjusted IPI (aaIPI), the revised IPI (R-IPI), 
and the National Comprehensive Cancer Network IPI (NCCN-IPI) at diagnosis in 63 
CD20-positive DLBCL patients treated with R-CHOP followed by upfront auto-SCT.
Results
At the time of auto-SCT, 74.6% and 25.4% of patients had achieved complete remission 
and partial remission after R-CHOP, respectively. As a whole, the 5-year overall (OS) and 
progression-free survival (PFS) rates were 78.8% and 74.2%, respectively. The 5-year OS 
and PFS rates according to the IPI, aaIPI, R-IPI, and NCCN-IPI did not significantly differ 
among the risk groups for each prognostic model (P-values for OS: 0.255, 0.337, 0.881, 
and 0.803, respectively; P-values for PFS: 0.177, 0.904, 0.295, and 0.609, respectively). 
Conclusion
There was no ideal prognostic model among those currently available for CD20-positive 
DLBCL patients treated with R-CHOP followed by upfront auto-SCT.
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INTRODUCTION
Prior to the rituximab era, the International Prognostic 
Index (IPI) and the age-adjusted IPI (aaIPI) were developed 
by the International Non-Hodgkin’s Lymphoma Prognostic 
Factors Project to predict long-term survival for patients 
with aggressive non-Hodgkin’s lymphoma (NHL) [1]. Since 
the advent of rituximab, Sehn et al. have proposed that 
the revised IPI (R-IPI) is a better predictor for 4-year pro-
gression-free survival (PFS) and overall survival (OS) of dif-
fuse large B-cell lymphoma (DLBCL) patients treated with 
rituximab, cyclophosphamide, doxorubicin, vincristine, and 
prednisone (R-CHOP) [2]. In addition, clinical data from 
the seven National Comprehensive Cancer Network (NCCN) 
member institutions demonstrated that the NCCN-IPI better 
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Table 1. Patient and disease characteristics at diagnosis.
N %
Gender
Male 36 57.1
Female 27 42.9
Age, years, median (range) 50 (22–66)
Ann Arbor Stage
1 or 2 with bulky disease 4 6.3
3 15 23.8
4 44 69.9
B symptomsa) 25 40.3
High LDH 50 80.6
Bulky disease 11 17.5
Extranodal sites ≥2 37 58.7
ECOG PS ≥2 15 23.8
a)B symptoms indicate systemic symptoms such as fever, night 
sweats, and weight loss, which are associated with non-Hodgkin’s
lymphoma.
Abbreviations: LDH, lactate dehydrogenase; ECOG, Eastern Coo-
perative Oncology Group; PS, performance status.
discriminated low and high risk subgroups than the IPI for 
patients with DLBCL treated with rituximab-containing che-
motherapy [3]. 
We confront uncertainty regarding the prognostic model 
that can differentiate the high risk group from the low risk 
group for patients with DLBCL treated with R-CHOP fol-
lowed by upfront autologous stem cell transplantation 
(auto-SCT). Previously, we showed that the 5-year OS and 
PFS rates did not differ between the risk groups according 
to the aaIPI and R-IPI [4]. In this study, we aimed to de-
termine which among the currently available prognostic 
models is most adoptable for DLBCL patients treated with 
R-CHOP followed by upfront auto-SCT. 
MATERIALS AND METHODS
Data sources
Data were collected from the Korean Blood and Marrow 
Transplant Registry (KBMTR). The KBMTR is a voluntary 
organization comprised of 43 transplantation centers located 
in South Korea. The Transplant Registration Committee re-
quires participating centers to submit detailed data from 
consecutive patients to the KBMTR. Informed consent is 
obtained on-site according to KBMTR regulations. The 
KBMTR database was used to identify adult patients with 
DLBCL who underwent upfront auto-SCT while in complete 
remission (CR) or partial remission (PR) after R-CHOP che-
moimmunotherapy between January of 2005 and March of 
2014. Additional data were obtained from each center to 
complete this study. 
Patients
We analyzed data obtained from 63 CD20-positive DLBCL 
patients who underwent R-CHOP therapy followed by 
high-dose consolidation therapy with autologous stem cell 
rescue between January of 2005 and March of 2014 as re-
ported to the KBMTR by 14 centers. Adult patients aged 
≥20 years were included. In Korea, the majority of medical 
expenses are covered and tightly regulated by the National 
Health Insurance System. All types of hematopoietic stem 
cell transplantation, including auto-SCT, are reviewed in 
advance by the Health Care Review and Evaluation 
Committee. The regulations allow auto-SCT for patients ≤65 
years old when their diseases are considered high risk. 
Therefore, the majority of patients enrolled in this study 
were ≤65 years old and having Ann Arbor stage III or 
IV disease. Four stage I or II patients with bulky disease 
underwent upfront auto-SCT because their diseases were 
considered advanced. This study was approved by the institu-
tional review board of Konkuk University Medical Center.
Assessment of responses
The 2007 revised guidelines of the International Harmoni-
zation Project were adopted to describe the response criteria 
for DLBCL [5]. CR was defined as the complete disappearance 
of all detectable clinical evidence of disease and disease- 
related symptoms if these were present before therapy. PR 
was defined as a ≥50% decrease in the sum of the product 
of the diameters (SPD) of up to 6 of the largest dominant 
nodes or nodal masses. Stable disease (SD) was defined as 
a case that failed to attain the criteria needed for CR or 
PR but did not fulfill those for progressive disease (PD). 
OS was defined as the time interval from the date of diagnosis 
to the date of death as a result of any cause or to the last 
follow-up. PFS was defined as the time interval from the 
date of diagnosis to the date of lymphoma progression, relapse 
from CR, or death as a result of any cause. 
Statistical analysis
The differences in the categorical variables among the 
study groups were analyzed with Pearson’s chi-square test 
and Fisher’s exact test. Survival curves were plotted using 
the Kaplan-Meier method and the confidence intervals were 
calculated using the standard error. The differences in surviv-
al among the groups with respect to variables were analyzed 
with the log-rank test. The P-values reported were 2-sided; 
a P＜ 0.05 was considered statistically significant. The stat-
istical analyses were performed with the Statistical Package 
for the Social Sciences (SPSS) version 17.0 software (SPSS 
Inc., Chicago, IL).
RESULTS
Patient and disease characteristics
The patient and disease characteristics at the time of diag-
nosis are summarized in Table 1. A total of 63 patients were 
evaluated in the study. The patients were classified as stage 
I/II with bulky disease (6.3%) or stage III/IV (93.7%). Bulky 
disease was defined by the presence of one of the following 
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Table 2. The numbers and percentages of patients classified into 
the risk groups of each prognostic model.
N %
IPI (score) (N=63)
Low (0 or 1) 6 9.5
Low intermediate (2) 20 31.7
High intermediate (3) 24 38.1
High (4 or 5)  13 20.6
Age-adjusted IPI (score) (N=54)  
Low (0) 1 1.9
Low intermediate (1) 9 16.7
High intermediate (2) 32 59.3
High (3)  12 22.2
Revised IPI (score) (N=63) 
Very good (0) 1 1.6
Good (1 or 2) 25 39.7
Poor (3, 4, or 5)  37 58.7
NCCN-IPI (score) (N=63)
Low (0 or 1) 1 1.6
Low intermediate (2 or 3) 33 52.4
High intermediate (4 or 5) 26 41.3
High (≥6) 3 4.8
Abbreviations: IPI, International Prognostic Index; NCCN, National 
Comprehensive Cancer Network.
Table 3. Treatments and responses before auto-SCT.
N %
R-CHOP cycles
4 or 5 15 23.8
6 33 52.4
7, 8, or 9 15 23.8
Response to R-CHOP
CR 47 74.6
PR 16 25.4
RT before SCT
Yes
Bulky disease 3 4.8
Remnant disease 3 4.8
No 57 90.5
Disease status at SCT
CR 47 74.6
PR 16 25.4
Abbreviations: auto-SCT, autologous stem cell transplantation; 
R-CHOP, rituximab+cyclophosphamide+adriamycin+vincristine+ 
prednisolone; CR, complete remission; PR, partial remission; RT, 
radiation therapy; SCT, stem cell transplantation.
Table 4. Transplantation characteristics.
N %
Median time to SCT, months (range)  7.2 (3.4–40.3)
Stem cell mobilization
Chemotherapy+G-CSF 60 95.2
G-CSF alone 3 4.8
Conditioning regimen
BU+CY+VP-16 20 31.7
BU+MEL+VP-16 22 34.9
MITO+VP-16+ARA-C+MEL 11 17.5
BCNU+VP-16+ARA-C+MEL 4 6.3
IFOS+CARB+VP-16 3 4.8
Others 3 4.8
 CD34+ cell dose, ×106/kg (range)  5.3 (1.1–50.5)
Median time to cell recovery after SCT
ANC, days (range) 12 (8–25)
PLT, days (range) 17 (2–391)
Abbreviations: SCT, stem cell transplantation; G-CSF, granulocyte- 
colony stimulating factor; BU, busulfan; CY, cyclophosphamide; 
VP-16, etoposide; MEL, melphalan; MITO, mitoxantrone; ARA-C, 
cytosine arabinoside; BCNU, carmustine; IFOS, ifosfamide; CARB, 
carboplatin; CD, cluster of differentiation; ANC, absolute neutrophil 
count; PLT, platelet.
2 findings: (1) an abdominal node or nodal mass with a 
largest dimension of ≥10 cm as determined by an imaging 
study or (2) a mediastinal mass with a maximum width 
equal to or greater than one-third of the internal transverse 
diameter of the thorax at the T5/6 level as determined by 
a imaging study. At diagnosis, the IPI, R-IPI, and NCCN-IPI 
were available for 63 patients; however, the aaIPI was only 
available for 54 patients due to the age criteria. The numbers 
and percentages of patients classified into the risk groups 
of each prognostic model (IPI, aaIPI, R-IPI, and NCCN-IPI) 
are documented in Table 2. 
Treatments before auto-SCT and transplantation 
characteristics
The treatments received by patients before auto-SCT and 
the transplantation characteristics are shown in Tables 3 
and 4, respectively. The CR and PR rates following R-CHOP 
therapy were 74.6% and 25.4%, respectively. Six patients 
received involved field radiotherapy (IFRT) for bulky disease 
or remnant lymphoma prior to auto-SCT. One of the 6 patients 
receiving IFRT experienced an upgrade in response from PR 
to CR. However, the overall response rates were not improved 
at the time of auto-SCT. The median time from diagnosis 
to auto-SCT was 7.2 months (range, 3.4–40.3 months).
Response to treatment and outcomes
The median durations of follow-up after diagnosis and 
auto-SCT for all enrolled patients were 57.3 months (range, 
6.3–110.7 months) and 46.3 months (range, 0.4–102.1 
months), respectively. The median durations of follow-up 
after diagnosis and auto-SCT for the surviving patients were 
60.2 months (range, 8.6–110.7 months) and 53.2 months 
(range, 3.6–102.1 months), respectively. During the fol-
low-up period, 16 patients eventually relapsed after au-
to-SCT. Four patients died of pneumonia or bacteremia, and 
8 died of lymphoma relapse. The 5-year OS and PFS rates 
were 78.8±5.5% and 74.2±5.8%, respectively.
Survival rates according to the IPI at diagnosis
The 5-year OS rates of the patients in the low (N=6), 
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Fig. 1. Probability of overall survival (OS) (A) and progression-free survival (PFS) (B) after autologous stem cell transplantation according to the 
International Prognostic Index (IPI) score at diagnosis.
Fig. 2. Probability of overall survival (OS) (A) and progression-free survival (PFS) (B) after autologous stem cell transplantation according to the 
age-adjusted International Prognostic Index (aaIPI) score at diagnosis.
low intermediate (N=20), high intermediate (N=24), and high 
(N=13) risk groups were 100%, 71.2±11.0%, 86.7±7.2%, and 
62.9±15.4%, respectively (P=0.255; Fig. 1A). The 5-year PFS 
rates of the patients in the same categories were 80±17.9%, 
57.9±11.5%, 86.5±7.3%, and 67.1±13.5%, respectively (P=0.177; 
Fig. 1B). 
We reclassified the IPI risk groups into 2 groups: low 
and low intermediate vs. high intermediate and high. The 
5-year OS rates of the patients in the low/low intermediate 
(N=26) and high intermediate/high (N=37) risk groups were 
78.7±8.5% and 78.5±7.4%, respectively (P=0.997). The 5-year 
PFS rates of the patients in the same categories were 
66.8±9.7% and 79.7±6.9%, respectively (P=0.186).
Survival rates according to the aaIPI at diagnosis
The 5-year OS rates of patients in the low (N=1), low 
intermediate (N=9), high intermediate (N=32), and high 
(N=12) risk groups were 100%, 100%, 72.6±8.3%, and 62.5± 
15.5%, respectively (P=0.337; Fig. 2A). The 5-year PFS rates 
of the patients in the same categories were 100%, 75.0±15.3%, 
69.6±8.5%, and 66.7±1.36%, respectively (P=0.904; Fig. 2B).
We reclassified the aaIPI risk groups into 2 groups: low 
and low intermediate vs. high intermediate and high. The 
5-year OS rates of patients in the low/low intermediate 
(N=10) and high intermediate/high (N=44) risk groups were 
100% and 70.2±7.3%, respectively (P=0.078). The 5-year 
PFS rates of the patients in the same categories were 77.8± 
13.9% and 68.8±7.2%, respectively (P=0.582).
Survival rates according to the R-IPI at diagnosis
The 5-year OS rates of the patients in the very good (N=1), 
good (N=25), and poor (N=37) risk groups were 100%, 77.7%, 
and 78.5±7.4%, respectively (P=0.881; Fig. 3A). The 5-year 
PFS rates of the patients in the same categories were 100%, 
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Fig. 3. Probability of overall survival (OS) (A) and progression-free survival (PFS) (B) after autologous stem cell transplantation according to the 
revised International Prognostic Index (R-IPI) score at diagnosis.
Fig. 4. Probability of overall survival (OS) (A) and progression-free survival (PFS) (B) after autologous stem cell transplantation according to the 
National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) score at diagnosis.
65.3±10.0%, and 79.7±6.9%, respectively (P=0.295; Fig. 3B).
We reclassified the R-IPI risk groups into 2 groups: very 
good and good vs. poor. The 5-year OS rates of the patients 
with very good/good (N=26) and poor risk (N=37) were 
78.7±8.5% and 78.5±7.4%, respectively (P=0.977). The 5-year 
PFS rates of the patients in the same categories were 66.8± 
10.3% and 79.7±6.9%, respectively (P=0.186).
Survival rates according to the NCCN-IPI at diagnosis
The 5-year OS rates of the patients with low (N=1), low 
intermediate (N=33), high intermediate (N=26), and high 
risk (N=3) were 100%, 77.3±7.6%, 76.6±9.5%, and 100%, 
respectively (P=0.803; Fig. 4A). The 5-year PFS rates of 
the patients in the same categories were 100%, 66.6±8.7%, 
79.3±8.3%, and 100%, respectively (P=0.609; Fig. 4B).
We reclassified the NCCN-IPI risk groups into 2 groups: 
low and low intermediate vs. high intermediate and high. 
The 5-year OS rates of the patients with low/low intermediate 
(N=34) and high intermediate/high risk (N=29) were 
78.0±7.4% and 78.9±8.7%, respectively (P=0.742). The 5-year 
PFS rates of the patients in the same categories were 
67.7±8.5% and 81.6±7.5%, respectively (P=0.401). The 5-year 
OS and PFS rates according to the IPI, aaIPI, R-IPI, and 
NCCN-IPI did not show statistically significant differences 
between the subgroups (P＞0.05) when the subjects were 
stratified by each prognostic risk model. 
DISCUSSION
High-dose chemotherapy with auto-SCT has been per-
formed for curative purposes and is now the treatment of 
choice in patients with relapsed, chemotherapy-sensitive 
DLBCL. In addition, auto-SCT has been applied in patients 
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Table 5. Outcomes of high risk diffuse large B-cell lymphoma patients treated with upfront autologous stem cell transplantation.
References Disease characteristics N Overall survival Progression-free survival Others
Haioun C et al. 
2000 [15]
aaIPI high-int or high risk 
aggressive NHL 
125 8-year OS 64% 8-year DFS 55% DLBCL 60%; aaIPI 2 81%; 
aaIPI 3 19%
Le Gouill S et al. 
2011 [6]
DLBCL 143 3-year OS 83% 3-year PFS 76%; 
3-year DFS 83%
aaIPI >1 58%
Schmitz N et al. 
2012 [7]
aaIPI high-int or high risk 
aggressive B-cell lymphoma
132 3-year OS 77% 3-year EFS 61.4%;
 3-year PFS 69.8%
DLBCL 78.3%; aaIPI 2 
73.5%; aaIPI 3 26.5%
Vitolo U et al. 
2012 [9]
aaIPI high-int or high risk DLBCL 199 3-year OS 81% 3-year PFS 70% aaIPI 2 74%; aaIPI 3 26%
Stiff PJ et al. 
2013 [8]
aaIPI high-int or high risk 
aggressive NHL
125 2-year OS 74% 2-year PFS 69% DLBCL 67%; aaIPI 2 68%; 
aaIPI 3 32%
Yoon JH et al. 
2015 [16]
aaIPI high-int or high risk DLBCL 23 3-year OS 75% 3-year PFS 66% aaIPI 2 78.3%; aaIPI 3 21.7%
Lee HG et al. 
2015 [This trial]
aaIPI high-int or high risk DLBCL 44 5-year OS 70.2% 5-year PFS 68.8% aaIPI 2 72.7%; aaIPI 3 27.3%
Abbreviations: aaIPI, age-adjusted International Prognostic Index; high-int, high intermediate; NHL, non-Hodgkin’s lymphoma; OS, overall 
survival; DFS, disease-free survival; DLBCL, diffuse large B-cell lymphoma; PFS, progression-free survival; EFS, event-free survival.
with high risk aggressive NHL to improve the outcome of 
consolidative treatment. Recent randomized studies showed 
no significant survival benefit to upfront auto-SCT compared 
with rituximab-containing chemoimmunotherapy alone for 
aggressive B-cell lymphoma [6-8]. However, a prospective 
randomized trial performed by Vitolo et al. demonstrated 
that the 3-year PFS was significantly higher in the upfront 
auto-SCT group compared with the non-auto-SCT group 
in patients with high risk DLBCL [9]. The role of upfront 
auto-SCT remains to be established with long-term follow-up 
in patients with high risk DLBCL. 
The IPI and aaIPI were developed to predict long-term 
survival for aggressive NHL, including DLBCL, before the 
introduction of rituximab to the medical field [1]. The IPI 
was also useful in predicting the outcome in patients with 
aggressive CD20-positive B-cell lymphoma treated with 
R-CHOP [10]. The IPI or aaIPI at diagnosis was found to 
be of value in predicting the OS and PFS in 25 patients 
with DLBCL who were treated with R-CHOP followed by 
upfront auto-SCT [11]. The 5-year OS and PFS of the high 
risk group were lower than those of the high intermediate 
risk group (P=0.04 and P=0.092, respectively). When the 
aaIPI was applied to 242 patients with relapsed CD20-positive 
DLBCL, an aaIPI score of 2 to 3 was a significant prognostic 
factor predicting 4-year OS and PFS after salvage auto-SCT 
(P＜0.001) [12]. In contrast, a French prospective multi-
center trial showed that 3-year PFS did not differ between 
the aaIPI high intermediate and high risk groups when 155 
patients with DLBCL were treated with rituximab combined 
with ACVBP (doxorubicin, cyclophosphamide, vindesine, 
bleomycin, and prednisolone) and upfront auto-SCT [13]. 
Another retrospective study showed that the 5-year OS and 
PFS did not significantly differ between the high inter-
mediate and high risk groups based on the aaIPI when 22 
patients with DLBCL were treated with rituximab-contain-
ing induction chemotherapy followed by upfront auto-SCT 
[14]. Here we summarize the representative survival data 
of patients with aaIPI high intermediate or high risk ag-
gressive NHL, including DLBCL, who were treated with 
upfront auto-SCT (Table 5) [7-9, 15, 16]. 
Sehn et al. reported that the R-IPI identified three distinct 
prognostic groups with a better predictive value of 4-year 
OS and PFS for patients with DLBCL treated with R-CHOP 
compared to the standard IPI [2]. The French trial, mentioned 
above, also analyzed the data regarding whether the out-
comes were different when the subjects were stratified ac-
cording to the R-IPI risk classification [13]. There were no 
differences in OS and PFS between the R-IPI good and poor 
risk groups. 
Recently, the NCCN-IPI has been proposed as a model 
with better discrimination of 5-year OS and PFS for patients 
with DLBCL treated with rituximab-containing chemo-
therapy as compared to the IPI for risk stratification [3]. 
So far, however, it has not been proved that the NCCN-IPI 
is a useful prognostic model for patients with DLBCL treated 
with rituximab-containing chemotherapy followed by up-
front auto-SCT. 
Because it was difficult to find an ideal prognostic model 
without controversy to predict outcomes for patients with 
DLBCL who were treated with chemoimmunotherapy fol-
lowed by upfront auto-SCT, we applied 4 prognostic models 
to the prediction of survival in our study: the IPI, aaIPI, 
R-IPI, and NCCN-IPI. Unfortunately, none of the models 
demonstrated a statistically significant difference for OS and 
PFS among the risk groups when the patients were stratified 
by each risk classification.
In conclusion, the OS and PFS rates according to the 
IPI, aaIPI, R-IPI, and NCCN-IPI did not significantly differ 
among the subgroups. There was no ideal prognostic model 
among the established ones for CD20-positive DLBCL pa-
tients who were treated with R-CHOP followed by upfront 
auto-SCT. A new prognostic model may be necessary to 
identify the patients who will gain the maximum benefit 
from upfront auto-SCT in the rituximab era.
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